Zhejiang Medicine Balance Sheet Health
Financial Health criteria checks 6/6
Zhejiang Medicine has a total shareholder equity of CN¥10.6B and total debt of CN¥749.2M, which brings its debt-to-equity ratio to 7.1%. Its total assets and total liabilities are CN¥13.4B and CN¥2.8B respectively. Zhejiang Medicine's EBIT is CN¥729.0M making its interest coverage ratio 79.8. It has cash and short-term investments of CN¥2.0B.
Key information
7.1%
Debt to equity ratio
CN¥749.20m
Debt
| Interest coverage ratio | 79.8x |
| Cash | CN¥1.96b |
| Equity | CN¥10.61b |
| Total liabilities | CN¥2.82b |
| Total assets | CN¥13.43b |
Recent financial health updates
Is Zhejiang Medicine (SHSE:600216) A Risky Investment?
Sep 14
Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet
Mar 29Recent updates
Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch
Nov 22We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings
Nov 01Is Zhejiang Medicine (SHSE:600216) A Risky Investment?
Sep 14What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You
Aug 06Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15
Jul 05The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet
Jun 21Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem
May 02Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet
Mar 29Financial Position Analysis
Short Term Liabilities: 600216's short term assets (CN¥6.1B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 600216's short term assets (CN¥6.1B) exceed its long term liabilities (CN¥462.0M).
Debt to Equity History and Analysis
Debt Level: 600216 has more cash than its total debt.
Reducing Debt: 600216's debt to equity ratio has reduced from 8% to 7.1% over the past 5 years.
Debt Coverage: 600216's debt is well covered by operating cash flow (122.2%).
Interest Coverage: 600216's interest payments on its debt are well covered by EBIT (79.8x coverage).